Among the 23 EGFR-mutated patients treated with erlotinib, 17 (74%) responded, 4 (17%) had no OR, and 2 (9%) harboring a SMAD4-mutation (p.R135*(stop)) and a FGFR3-mutation (p.D785fs*31), respectively, showed mixed response with simultaneously progressing and responding tumor lesions (Tables 1 and 2). Here, SMAD4 is linked to neoplasm.